Allogeneic Double-Negative CAR-T Cells Inhibit Tumor Growth without Off-Tumor Toxicities

To overcome the challenges faced with CAR-T cells using donor-derived conventional CD4+ or CD8+ T cells, scientists evaluated the feasibility, safety, and efficacy of using healthy donor–derived allogeneic double-negative T cells as a CAR-T cell therapy platform.